Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F4,F5	Apr 7, 2017	S	69,667	$11.7163	D	648,927	I	Through Deerfield Special Situations Fund, L.P.
Common Stock^F1,F4,F5	Apr 7, 2017	S	22,009	$11.7163	D	837,132	I	Through Deerfield Partners, L.P.
Common Stock^F1,F4,F5	Apr 7, 2017	S	27,228	$11.7163	D	1,035,646	I	Through Deerfield International Master Fund, L.P.
Common Stock^F2,F4,F5	Apr 10, 2017	S	46,730	$11.0375	D	602,197	I	Through Deerfield Special Situations Fund, L.P.
Common Stock^F2,F4,F5	Apr 10, 2017	S	14,763	$11.0375	D	822,369	I	Through Deerfield Partners, L.P.
Common Stock^F2,F4,F5	Apr 10, 2017	S	18,264	$11.0375	D	1,017,382	I	Through Deerfield International Master Fund, L.P.
Common Stock^F3,F4,F5	Apr 11, 2017	S	19,593	$11.0125	D	582,604	I	Through Deerfield Special Situations Fund, L.P.
Common Stock^F3,F4,F5	Apr 11, 2017	S	6,189	$11.0125	D	816,180	I	Through Deerfield Partners, L.P.
Common Stock^F3,F4,F5	Apr 11, 2017	S	7,658	$11.0125	D	1,009,724	I	Through Deerfield International Master Fund, L.P.

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.70 to $11.83, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2) and (3) of this Form 4.
F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.26, inclusive.
F3The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $11.00 to $11.15, inclusive.
F4This Form 4 is being filed by the undersigned as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Deerfield Mgmt, L.P. is the general partner of Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P. (collectively, the "Funds"). Deerfield Management Company, L.P. is the investment manager of the Funds. James E. Flynn is the sole member of the general partner of each of Deerfield Mgmt, L.P. and Deerfield Management Company, L.P.
F5In accordance with Instruction 4 (b)(iv) to Form 4, the entire amount of the Issuer's securities held by the Funds is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Remarks

Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to Editas Medicine, Inc. filed with the Securities and Exchange Commission on February 2, 2016 by Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Healthcare Innovations Fund, L.P., Deerfield Mgmt HIF, L.P., Deerfield Private Design Fund III, L.P. and James E. Flynn.